ScheelevAegen 22
Lund 223 63
Sweden
46 46 16 56 70
https://www.hansabiopharma.com
Settore/i:
Settore:
Impiegati a tempo pieno: 150
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Søren Tulstrup M.Sc | Pres & CEO | 13,91M | N/D | 1965 |
Mr. Donato Spota | CFO & Sr. VP | N/D | N/D | 1971 |
Dr. Christian Kjellman | Sr. VP, Chief Scientific Officer & COO | N/D | N/D | 1967 |
Ms. Eva-Maria Joed | VP of Fin. & Admin. | N/D | N/D | 1969 |
Mr. Klaus Sindahl | Head of Investor Relations | N/D | N/D | N/D |
Ms. Katja Margell | Head of Corp. Communications | N/D | N/D | N/D |
Ms. Anne Säfström Lanner | Sr. VP & Chief HR Officer | N/D | N/D | 1969 |
Mr. Emanuel Björne | VP & Head of Bus. Devel. | N/D | N/D | 1973 |
Dr. Lena Winstedt | Head of Science | N/D | N/D | 1969 |
Mr. Henk J. Doude van Troostwijk | Sr. VP & Chief Commercial Officer | N/D | N/D | 1965 |
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase, and efgartigimod, argenx's FcRn antagonist, to potentially unlock additional therapeutic value in both the acute and chronic setting of autoimmune diseases and transplantation. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
L'ISS Governance QualityScore di Hansa Biopharma AB (publ) al 1 febbraio 2023 è 2. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 6.